A retrospective study of 1,845 patients with type 2 diabetes showed that treatment with a GLP-1 receptor agonist (GLP-1 RA) reduced the risk of osteoporosis compared to untreated patients.[1][2] Out of 1845 patients, 256 were treated with GLP-1 RA, which is 13.88%.[1] The incidence of osteoporosis was significantly lower in the GLP-1 RA group (P < 0.01), with a total of 676 patients (36.6%) developing osteoporosis.[2] In the fully adjusted Cox model, the risk was reduced with a hazard ratio (HR) of 0.69 (95% CI 0.45–0.84, P < 0.05).[1][2] The protective effect was consistent across age, sex, BMI, smoking, and antihypertensive medication (P for interaction > 0.05).[1][2] The study supports the potential protective effects of GLP-1 RA on bone in patients with T2DM, but recommends further randomized controlled trials.[1][2]